32770-97-1

Basic information

• Product Name: 5-Benzothiazolemethanol,2-methyl-(6CI,8CI,9CI)
• Synonyms: 5-Benzothiazolemethanol,2-methyl-(6CI,8CI,9CI);(2-Methyl-1,3-benzothiazol-5-yl)methanol
• CAS NO: 32770-97-1
• Molecular Formula: C₉H₉NOS
• Molecular Weight: 179.23886
• Product Categories: BENZOTHIAZOLE
• Mol File: 32770-97-1.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-Benzothiazolemethanol,2-methyl-(6CI,8CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Benzothiazolemethanol,2-methyl-(6CI,8CI,9CI)(32770-97-1)
• EPA Substance Registry System: 5-Benzothiazolemethanol,2-methyl-(6CI,8CI,9CI)(32770-97-1)

Safety Data

• Hazardous Substances Data: 32770-97-1(Hazardous Substances Data)

Upstream product

• 24851-69-2 2-methylbenzo[d]thiazole-5-carboxylic acid 
• 2363-16-8 methyl 4-bromo-3-nitrobenzoate 
• 74-11-3 para-chlorobenzoic acid 
• 35350-37-9 methyl 4-[[4-(methoxycarbonyl)-2-nitrophenyl]disulfanyl]-3-nitrobenzoate 
• 14719-83-6 methyl 3-nitro-4-chlorobenzoate 
• 96-99-1 4-chloro-3-nitrobenzoate 
• 32770-98-2 2-methyl-5-benzothiazolecarxylic acid methyl ester 

Downstream Products

• 103264-09-1 (2-methyl-benzothiazol-5-yl)-acetic acid 
• 103754-68-3 (2-methyl-benzothiazol-5-yl)-acetonitrile 
• 20077-87-6 1-(2-methylbenzo[d]thiazol-5-yl)ethan-1-ol 
• 131868-38-7 diethyl-(2-methyl-benzothiazol-5-ylmethyl)-amine 
• 20077-88-7 1-(2-methylbenzo[d]thiazol-5-yl)ethan-1-one 
• 20061-46-5 2-methyl-1,3-benzothiazole-5-carbaldehyde 
• 99849-18-0 5-chloromethyl-2-methyl-benzothiazole 
• 103989-03-3 5-acetoxymethyl-2-methyl-benzothiazole 

Relevant articles and documents

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

Total synthesis and antitumor activity of ZK-EPO: The first fully synthetic epothilone in clinical development

Going to trial: From about 350 active epothilone analogues synthesized by a highly convergent synthesis, one (ZK-EPO, see picture) has been chosen for clinical development on the basis of its outstanding preclinical data. This compound exhibits higher activity and efficacy than taxanes (e.g. paclitaxel) and second-generation epothilones, a fast and efficient cellular uptake, no recognition by efflux mechanisms, and an improved therapeutic window. (Chemical Equation Presented)